Abstract
Background Given the fundamental physiological differences between the sexes, this study aimed to investigate the effect of metabolic syndrome on ventilatory defects stratified by sex.
Methods We conducted a nationwide, pooled, cross-sectional study. Data of 45,788 participants (men, n=15,859; women, n=29,929) aged 30 years or more were obtained from the Taiwan Biobank. Age-sex adjusted and multivariate logistic regression models were used to estimate the risk of developing impaired pulmonary function (restrictive or obstructive ventilatory defect) in individuals with or without metabolic syndromes. Separate models were also used to estimate for the risk of metabolic syndrome scores and the risk of individual metabolic abnormalities on the risk of restrictive ventilatory defect.
Results The overall prevalence of metabolic syndrome was estimated to be 15.9% in Taiwan, much higher in men than in women (18.6% versus 14.4%). Significant association was observed on the effect of metabolic syndromes on the risk of restrictive ventilatory defect. The risk of developing restrictive ventilator defect was 35% higher in participants with metabolic syndromes (odds ratio, 1.35; 95% confidence interval, 1.26-1.45) than those without metabolic syndromes. Elevated blood pressure and triglycerides abnormality were important predictors of restrictive ventilator defect.
Sex-stratified subgroup analyses of the individual metabolic abnormalities indicated that men with abdominal obesity and women with dysglycemia were more likely to develop restrictive ventilatory defect.
Conclusion Our study evidences suggested that metabolic syndromes were important predictors of impaired pulmonary function and increased risk of developing restrictive ventilatory defects, and its risk increased with increasing numbers of metabolic abnormalities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the Institutional Review Boards of MacKay Memorial Hospital in Taiwan (No. 21MMHIS351e).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data availability statement
The data that support the findings of this study are available from the Taiwan Biobank but restrictions apply to the availability of these data, which were used under license for this study. Data are however available from the authors upon reasonable request with the permission of Taiwan Biobank.
